Mytolac (Lanreotide Acetate)

Lanreotide acetate mimics natural somatostatin and binds to somatostatin receptors (mainly SSTR2 and SSTR5). This binding blocks the release of several hormones, including growth hormone and gastrointestinal peptides, thereby reducing disease‑related hormone excess.

The specific dose and dosing interval of Mytolac are determined by the prescribing clinician based on the patient’s condition, response, and tolerability. Healthcare professionals tailor the regimen to each individual case.

Safety data for lanreotide acetate in pregnancy and lactation are limited. It should only be used if the potential benefit justifies any possible risk to the fetus or infant, and the decision must be made by a qualified healthcare provider.

To request Mytolac, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain where required) and necessary import documentation.

Mytolac (lanreotide acetate) and other agents such as octreotide share the same mechanism of receptor binding but differ in formulation, dosing frequency, and pharmacokinetic profile. Lanreotide often allows for longer dosing intervals, which can reduce injection frequency compared with some alternatives.

Mytolac should be stored refrigerated at 2‑8 °C, protected from light, and must not be frozen or shaken. Keep the product in its original packaging until use to maintain stability.

Mytolac is given by subcutaneous injection. The injection is typically performed by a healthcare professional or a trained patient following aseptic technique, using the supplied device or syringe as directed by the prescribing clinician.

Serious adverse events include gallstone formation, pancreatitis, severe hyperglycaemia, allergic reactions such as anaphylaxis, and rare cardiovascular complications. Patients should be monitored regularly for these conditions and instructed to report any concerning symptoms promptly.

Mytolac is contraindicated in patients with known hypersensitivity to lanreotide acetate or any excipients in the formulation. Caution is advised for individuals with active gallbladder disease, uncontrolled diabetes, severe pancreatitis, or significant cardiac disorders, and the drug should be avoided in these situations unless benefits outweigh risks.